Search Results

You are looking at 11 - 20 of 44 items for :

  • "neuroendocrine tumour" x
Clear All
Open access

Richard P Steeds, Vandana Sagar, Shishir Shetty, Tessa Oelofse, Harjot Singh, Raheel Ahmad, Elizabeth Bradley, Rachel Moore, Suzanne Vickrage, Stacey Smith, Ivan Yim, Yasir S Elhassan, Hema Venkataraman, John Ayuk, Stephen Rooney and Tahir Shah

Introduction Neuroendocrine tumours (NETs) of gastrointestinal origin (GI NET) synthesise and release various hormones, including 5-hydroxytryptamine (5-HT). These hormones drain from the primary lesion and local lymph node metastases via the

Open access

Stefan Schulz, Anika Mann, Benjamin Novakhov, Hugh D Piggins and Amelie Lupp

=12); cervical carcinoma ( n =13); urinary bladder carcinoma ( n =8); prostate carcinoma ( n =7); neuroendocrine tumours ( n =23); growth hormone (GH)-producing pituitary adenoma ( n =21) and pheochromocytoma ( n =5). Several of the tumours contained

Open access

Filippo Ceccato, Diego Cecchin, Michele Gregianin, Giacomo Ricci, Cristina Campi, Filippo Crimì, Marta Bergamo, Annibale Versari, Carmelo Lacognata, Federico Rea, Mattia Barbot and Carla Scaroni

Introduction and Aim: Ectopic ACTH secretion (EAS) is mostly secondary to thoracic/abdominal neuroendocrine tumours (NETs), or small cell-lung carcinoma (SCLC). We studied the diagnostic accuracy of computed tomography (CT) with 68Ga-Dota derivatives (68Ga-SSTR) positron emission tomography (PET) in localizing ACTH-secreting tumor in patients with EAS.

Materials and Methods: 68Ga-SSTR-PET/CT was performed and compared with the nearest enhanced CT in 18 cases (16 primary and 2 recurrent neoplasms). Unspecific, indeterminate and false positive uptakes were assessed using conventional imaging, follow-up or histology.

Results: We diagnosed 13 thoracic (9 primary and 2 recurrent bronchial carcinoids, 2 SCLCs) and 1 abdominal (pancreatic NET) tumors. 8 ACTH-secreting tumors were promptly identified at EAS diagnosis ('overt', 4 pulmonary carcinoids with 2 recurrences, and 2 SCLC); 6 EAS have been discovered during the subsequent follow-up ('covert', 5 bronchial carcinoids and 1 pancreatic NET). At the time of EAS diagnosis, imaging was able to correctly detect the ACTH-secreting tumour in 8/18 cases (6 new diagnosis and 2 recurrences). During the follow-up, 6 out of initially 10 'occult' cases became 'covert'. At last available follow-up, CT and 68Ga-SSTR-PET/CT were able to diagnose respectively 11/18 and 12/18 ACTH-secreting tumours (respectively 11/14 and 12/14 considering only overt and covert cases). 4 cases have never been localized by conventional or nuclear imaging ('occult' EAS), despite an average follow up of 5 years.

Conclusions: The 68Ga-SSTR-PET/CT is useful in localizing EAS, especially to enhance positive prediction of the suggestive CT lesions and to detect occult neoplasms.

Open access

Matilde Calanchini, Michael Tadman, Jesper Krogh, Andrea Fabbri, Ashley Grossman and Brian Shine

tool for diagnosing and the monitoring of patients with NENs ( 18 , 24 ). At present, the European Neuroendocrine Tumour Society ( 18 ), the UK and Ireland Neuroendocrine Tumour Society ( 25 ) and the North American Neuroendocrine Tumour Society ( 26

Open access

Majunath R Goroshi, Swati S Jadhav, Anurag R Lila, Rajeev Kasaliwal, Shruti Khare, Chaitanya G Yerawar, Priya Hira, Uday Phadke, Hina Shah, Vikram R Lele, Gaurav Malhotra, Tushar Bandgar and Nalini S Shah

small-cell carcinoma of lung), majority of cases of EAS are now reported to be caused by neuroendocrine tumours (NETs) that include carcinoid tumours of bronchopulmonary system, thymus, and gastrointestinal tract; pancreatic NETs; medullary thyroid

Open access

Małgorzata Fuksiewicz, Maria Kowalska, Agnieszka Kolasińska-Ćwikła, Jarosław B Ćwikła, Łukasz Sawicki, Katarzyna Roszkowska-Purska, Joanna Drygiel and Beata Kotowicz

, chromogranin A; NEN, neuroendocrine neoplasm; OS, overall survival. Discussion The most common location of neuroendocrine tumours is the digestive system (GEP-NEN GEP). The diagnosis is usually made at the advanced stage of the disease when

Open access

Yang Lv, Ning Pu, Wei-lin Mao, Wen-qi Chen, Huan-yu Wang, Xu Han, Yuan Ji, Lei Zhang, Da-yong Jin, Wen-Hui Lou and Xue-feng Xu

.1001/jamaoncol.2017.0589 28448665 2 Huguet I Grossman AB O’Toole D. Changes in the epidemiology of neuroendocrine tumours . Neuroendocrinology 2017 104 105 – 111 . ( ) 10.1159/000441897 26505990 3 Yao JC Hassan M

Open access

R C S van Adrichem, L J Hofland, R A Feelders, M C De Martino, P M van Koetsveld, C H J van Eijck, R R de Krijger, D M Sprij-Mooij, J A M J L Janssen and W W de Herder

index. References 1 Modlin IM Oberg K Chung DC Jensen RT de Herder WW Thakker RV Caplin M Delle Fave G Kaltsas GA Krenning EP . Gastroenteropancreatic neuroendocrine tumours . Lancet Oncology 2008 9 61 – 72 . ( doi:10

Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study . Lancet: Oncology 2015 16 695 – 703 . ( ) 10.1016/S1470-2045(15)70136-1 5 Strosberg JR Cives M Hwang J Weber T Nickerson M Atreya CE Venook

Open access

Samira M Sadowski, Emanuel Christ, Benoit Bédat, Attila Kollár, Wolfram Karenovics, Aurel Perren, Frédéric Triponez and on behalf of the SwissNET registry

Paniagua JM Ramos G Canizares MA Muguruza I & Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung for the Spanish Society of Pneumonology and Thoracic Surgery. Typical and atypical carcinoid tumours: analysis of the